
    
      This is a pilot Phase II, prospective, double-blind, placebo-controlled study to compare the
      efficacy, safety and tolerability of rHuPH20 or placebo control administered intradermally
      (ID) in the prevention and treatment of subjects with contact allergy to nickel. This study
      will involve two treatment regimens, which will run in parallel (Treatment Regimens 1 and 2).
    
  